



Journal of Hospital Pharmacy
An Official Publication of Bureau for Health & Education Status Upliftment
(Constitutionally Entitled as Health-Education, Bureau)

A review on “Clinical Outcomes, Compliance, and Toxicity of Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Buccal Mucosa Cancer- a prospective observational study”

Ms. Muskan Rattan¹, Dr. Divya Singh², Dr. Rakesh Kumar Gupta³, Ms. Smriti Ray⁴

¹Department of Pharmacology, Jaipur College of Pharmacy, Sitapura, Jaipur

²Professor & HOD (Department of Pharmacology), Jaipur College of Pharmacy, Sitapura, Jaipur

³Professor, Jaipur College of Pharmacy, Sitapura, Jaipur

⁴Assistant Professor, Jaipur College of Pharmacy, Sitapura, Jaipur

Email Id: serviceheb@gmail.com

ABSTRACT

Buccal mucosa carcinoma constitutes a prominent subsite of oral squamous cell carcinoma and is disproportionately encountered in South Asia populations, largely due to habitual exposure to tobacco, areca nut, and betel quid. A considerable number of patients are diagnosed at a locally advanced stage, at which point surgical intervention is frequently rendered impractical. In such scenarios, concurrent chemoradiotherapy (CCRT), involving the integration of external beam radiotherapy with platinum-based systemic agents, is widely adopted as a definitive or organ-preserving therapeutic strategy. Nevertheless, the effectiveness of this approach is often influenced by treatment-induced toxicities and interruptions, particularly under real-world clinical conditions. Prospectively collected evidence focusing specifically on locally advanced buccal mucosa cancer (LABMC) remains sparse. This review consolidates available data on clinical outcomes, treatment compliance, and toxicity patterns associated with CCRT in locally advanced buccal mucosa cancer thereby highlighting the necessity for focused prospective observational evaluations.

Keywords: Buccal mucosa carcinoma, concurrent chemoradiotherapy, locally advanced disease, platinum compounds, treatment adherence, toxicity spectrum, therapeutic outcomes, prospective observation

Access this Article Online	Quick Response Code:
Website: http://www.journalofhospitalpharmacy.in	
Received on 16/12/2025	
Accepted on 29/12/2025 © HEB All rights reserved	

